var title_f23_42_24224="Skin abscess from epidermal inclusion cyst";
var content_f23_42_24224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidermal inclusion cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    It is common for epidermal inclusion cysts of the breast to become infected, requiring incision and drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24224=[""].join("\n");
var outline_f23_42_24224=null;
var title_f23_42_24225="A decapitating fly with IFA";
var content_f23_42_24225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Biologic control of imported fire ant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a Pseudacteon tricuspis decapitating fly preparing to attack an imported fire ant&nbsp;worker. Decapitating flies have been proposed as a means of biologic control of imported fire ants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Williams DF, deShazo RD. Biological control of fire ants: an update on new techniques. Ann Allergy Asthma Immunol 2004; 93:15. Copyright &copy; 2004 American Academy of Allergy, Asthma, and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24225=[""].join("\n");
var outline_f23_42_24225=null;
var title_f23_42_24226="Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)";
var content_f23_42_24226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16840\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"         Upper digestive tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?30/7/30843\">",
"          Medicines used to treat acid reflux",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/55/23411\">",
"         Patient information: Pregnancy symptoms (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/56/37762\">",
"         Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/30/38373\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/acid-reflux-gastroesophageal-reflux-disease-during-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12090406\">",
"      <span class=\"h1\">",
"       What is acid reflux?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Acid reflux is when the acid that is normally in your stomach backs up into your esophagus (",
"      <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"       figure 1",
"      </a>",
"      ). The esophagus is the tube that carries food from your mouth to your stomach. Another term for acid reflux is &ldquo;gastroesophageal reflux disease,&rdquo; or GERD.",
"     </p>",
"     <p>",
"      Many women get acid reflux during pregnancy. Acid reflux usually gets worse over the course of the pregnancy. It usually goes away after the baby is born.",
"     </p>",
"     <p>",
"      Women who have acid reflux in one pregnancy are likely to get it again in future pregnancies.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090421\">",
"      <span class=\"h1\">",
"       What are the symptoms of acid reflux during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms of acid reflux during pregnancy are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Burning in the chest, known as heartburn",
"       </li>",
"       <li>",
"        Burning in the throat or an acid taste in the mouth",
"       </li>",
"       <li>",
"        Stomach or chest pain",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Trouble swallowing",
"       </li>",
"       <li>",
"        A raspy voice or sore throat",
"       </li>",
"       <li>",
"        A cough",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090436\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor or nurse should be able to tell if you have it by talking with you and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090451\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to improve my symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help with your symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat 4 to 6 small meals a day, instead of 3 large ones.",
"       </li>",
"       <li>",
"        Avoid lying down within 3 hours of eating.",
"       </li>",
"       <li>",
"        Avoid eating within 3 hours of bedtime.",
"       </li>",
"       <li>",
"        Avoid wearing tight-fitting clothes.",
"       </li>",
"       <li>",
"        Avoid foods that make your symptoms worse. Foods that commonly make acid reflux worse are coffee, cola, tea, citrus foods, chocolate, and fatty foods.",
"       </li>",
"       <li>",
"        Raise the head of your bed by 6 to 8 inches (15 to 20 cm). You can do this by putting blocks of wood under 2 legs of the bed or using a Styrofoam wedge under your pillow.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090466\">",
"      <span class=\"h1\">",
"       Are there treatments that can help reduce symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are 3 main types of medicines that can reduce acid reflux symptoms. They are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Antacids",
"       </li>",
"       <li>",
"        Histamine blockers",
"       </li>",
"       <li>",
"        Proton pump inhibitors",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these medicines work by reducing or blocking stomach acid. But each of them does that in a different way (",
"      <a class=\"graphic graphic_table graphicRef78918 \" href=\"UTD.htm?30/7/30843\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Doctors usually recommend that pregnant women first try antacids to reduce their symptoms. You can buy antacids without a prescription.",
"     </p>",
"     <p>",
"      If antacids don&rsquo;t help enough, let your doctor or nurse know. He or she might recommend that you try a histamine blocker or proton pump inhibitor. These medicines work better than antacids to reduce symptoms. You can buy most histamine blockers and some proton pump inhibitors without a prescription.",
"     </p>",
"     <p>",
"      Before you use any over-the-counter medicines for acid reflux, talk to your doctor or nurse. He or she can tell you which ones are safe to use during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090481\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have severe heartburn or chest pain, or these symptoms don&rsquo;t get better with treatment",
"       </li>",
"       <li>",
"        Have a fever, headache, nausea, or vomiting with your heartburn",
"       </li>",
"       <li>",
"        Choke when you eat, have trouble swallowing, or feel like food is getting &ldquo;stuck&rdquo; on the way down your throat",
"       </li>",
"       <li>",
"        Lose weight without trying",
"       </li>",
"       <li>",
"        Vomit bright red blood or material that looks like coffee grounds",
"       </li>",
"       <li>",
"        Have bowel movements that look like black tar",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090496\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/56/37762?source=see_link\">",
"       Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/55/23411?source=see_link\">",
"       Patient information: Pregnancy symptoms (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/42/24226?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16840 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24226=[""].join("\n");
var outline_f23_42_24226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090406\">",
"      What is acid reflux?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090421\">",
"      What are the symptoms of acid reflux during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090436\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090451\">",
"      Is there anything I can do on my own to improve my symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090466\">",
"      Are there treatments that can help reduce symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090481\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090496\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16840\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"      Upper digestive tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?30/7/30843\">",
"       Medicines used to treat acid reflux",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/55/23411?source=related_link\">",
"      Patient information: Pregnancy symptoms (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/56/37762?source=related_link\">",
"      Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_42_24227="MRI brain sagging";
var content_f23_42_24227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    MRI of brain sagging with low cerebrospinal fluid pressure headache",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Brain MRI of a patient with low cerebrospinal fluid (CSF) pressure headache (spontaneous intracranial hypotension). Noncontrast T1-weighted sagittal images were obtained&nbsp;before (A) and after (B) treatment. There is crowding and pointing of the cerebellar tonsils at the foramen magnum mimicking a Chiari 1 malformation on the first study (black arrow, image A). In addition, there is sagging of the brain resulting in inferior displacement of the floor of the third ventricle (white arrow, image A) as well as loss of CSF space in the suprasellar cistern. These findings have resolved on MRI six months later after treatment (B), which included draining of associated subdural collections.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24227=[""].join("\n");
var outline_f23_42_24227=null;
var title_f23_42_24228="Neomycin, polymyxin B, and hydrocortisone: Drug information";
var content_f23_42_24228=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin, polymyxin B, and hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/38/12901?source=see_link\">",
"    see \"Neomycin, polymyxin B, and hydrocortisone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38179?source=see_link\">",
"    see \"Neomycin, polymyxin B, and hydrocortisone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin&reg;;",
"     </li>",
"     <li>",
"      Cortomycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortimyxin&reg;;",
"     </li>",
"     <li>",
"      Cortisporin&reg; Otic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic;",
"     </li>",
"     <li>",
"      Antibiotic, Otic;",
"     </li>",
"     <li>",
"      Antibiotic, Topical;",
"     </li>",
"     <li>",
"      Antibiotic/Corticosteroid, Otic;",
"     </li>",
"     <li>",
"      Corticosteroid, Ophthalmic;",
"     </li>",
"     <li>",
"      Corticosteroid, Otic;",
"     </li>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Duration of use of ophthalmic and otic preparations should be limited to 10 days unless otherwise directed by the healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Auditory canal inflammation/infection:",
"     </b>",
"     Otic: Instill 4 drops 3-4 times/day; otic suspension is the preferred otic preparation.",
"     <b>",
"      Note:",
"     </b>",
"     Otic solution is used",
"     <b>",
"      only",
"     </b>",
"     for bacterial infections of external auditory canal (eg, swimmer&rsquo;s ear).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ocular inflammation/infection:",
"     </b>",
"     Ophthalmic: Instill 1-2 drops 2-4 times/day, or more frequently as required for severe infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dermatologic inflammation/infection:",
"     </b>",
"     Topical: Apply a thin layer 1-4 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38179?source=see_link\">",
"      see \"Neomycin, polymyxin B, and hydrocortisone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Duration of use of ophthalmic and otic preparations should be limited to 10 days unless otherwise directed by the healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Auditory canal inflammation/infection:",
"     </b>",
"     Otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6 months to 2 years (unlabeled use): Instill 3 drops into affected ear 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years: Instill 3 drops into affected ear 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Otic solution is used",
"     <b>",
"      only",
"     </b>",
"     for bacterial infections of external auditory canal (eg, swimmer&rsquo;s ear).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ocular inflammation/infection:",
"     </b>",
"     Ophthalmic: Children (unlabeled use): Instill 1-2 drops 2-4 times/day, or more frequently as required for severe infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatologic inflammation/infection:",
"     </b>",
"     Topical: Children (unlabeled use): Apply a thin layer 1-4 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortisporin&reg;: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone acetate 5 mg per g (7.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL) [contains potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortisporin&reg;: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL) [contains potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortomycin: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL) [contains potassium metabisulfate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (7.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, otic: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortomycin: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL) [contains thimerosal]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes topical cream",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake otic suspension well before using. Otic preparations should not be used when the integrity of the tympanic membrane is in question.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steroid-responsive inflammatory condition for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. For additional information, see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic ointment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Delayed wound healing, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataracts, corneal thinning, glaucoma, irritation, keratitis (bacterial), intraocular pressure increase, optic nerve damage, scleral thinning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (including anaphylaxis), secondary infection, sensitization to kanamycin, paromomycin, streptomycin, and gentamicin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Otic solution and suspension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic contact dermatitis, burning skin, dryness, folliculitis, hypertrichosis, hypopigmentation, irritation, maceration of skin, miliaria, ocular hypertension, perioral dermatitis, pruritus, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Burning, ototoxicity, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (including anaphylaxis), secondary infection, sensitization to karamycin, paromycin, streptomycin, and gentamicin",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin, polymyxin B, hydrocortisone, or any component of the formulation; not for use in viral infections, fungal diseases, mycobacterial infections",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5440920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin sensitization: Symptoms of neomycin sensitization include itching, reddening, edema, and failure to heal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ototoxicity (otic preparations): Risk of ototoxicity is increased in patients with extended use or tympanic perforation; avoid use with tympanic perforation, limit therapy to 10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some formulations may contain sulfites, which may cause allergic-type reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14287268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cortisporin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-0.5-10000 (7.5 g): $67.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cortisporin Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-10000-1 (10 mL): $103.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neomycin-Polymyxin-HC Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-10000-1 (10 mL): $30.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Neomycin-Polymyxin-HC Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-10000-1 (10 mL): $30.80",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin Cream (BB, BM, BS, BZ, GY, JM, NL, PK, SR, TT);",
"     </li>",
"     <li>",
"      Cortisporin Ear (BB, BM, BS, BZ, GY, JM, NL, PH, SR, TT);",
"     </li>",
"     <li>",
"      Cortisporin Ophthalmic Suspension (BB, BM, BS, BZ, GY, JM, NL, SR, TT);",
"     </li>",
"     <li>",
"      Ircos (PH);",
"     </li>",
"     <li>",
"      Isonep H (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9690 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-335F5A8ACC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24228=[""].join("\n");
var outline_f23_42_24228=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200652\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200653\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200664\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200654\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200659\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200655\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200644\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200632\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200646\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200645\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200662\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200649\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5440920\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200660\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200639\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200640\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287265\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287268\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287267\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422267\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200650\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200635\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200648\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/38/12901?source=related_link\">",
"      Neomycin, polymyxin B, and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38179?source=related_link\">",
"      Neomycin, polymyxin B, and hydrocortisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_42_24229="Leflunomide: Patient drug information";
var content_f23_42_24229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Leflunomide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     see \"Leflunomide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arava&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Leflunomide&reg;;",
"     </li>",
"     <li>",
"      Arava&reg;;",
"     </li>",
"     <li>",
"      Mylan-Leflunomide;",
"     </li>",
"     <li>",
"      Novo-Leflunomide;",
"     </li>",
"     <li>",
"      PHL-Leflunomide;",
"     </li>",
"     <li>",
"      PMS-Leflunomide;",
"     </li>",
"     <li>",
"      Sandoz-Leflunomide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use a helpful kind of birth control during care and after care ends. A pregnancy test will be done to show that you are NOT pregnant before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702365",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to leflunomide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700917",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        Do not use this drug if you are pregnant and do not get pregnant.",
"       </b>",
"       Use birth control that you can trust. At the end of care, you will need to get rid of the extra leflunomide in your body. Taking a drug called cholestyramine 3 times a day for 11 days will get rid of most of the drug. Talk with your doctor if you want to get pregnant. You will need to have blood tests showing that your body is free of leflunomide before you stop taking birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease or if you have had hepatitis B or hepatitis C infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697151",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak immune system or very bad infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your white blood cell, red blood cell, or platelet counts are low, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696744",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not donate blood while using this drug and for 3 months after stopping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy. At the end of care, you will have a process to get rid of the extra leflunomide in your body. Taking a drug called cholestyramine 3 times a day for 11 days will get rid of most of the drug. Talk with your doctor if you want to get pregnant. You will need to have blood tests showing that your body is free of leflunomide before you stop taking birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698517",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, have your blood work checked after finishing cholestyramine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lung infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant during or after care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need a TB (tuberculosis) test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a pregnancy test before starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10793 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24229=[""].join("\n");
var outline_f23_42_24229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187137\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027762\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027764\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027763\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027768\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027769\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027771\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027766\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027767\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027772\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027773\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=related_link\">",
"      Leflunomide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_42_24230="Uric acid balance";
var content_f23_42_24230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uric acid balance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/42/24230/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/42/24230/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/42/24230/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/42/24230/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/42/24230/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/42/24230/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/42/24230/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uric acid is the end product of the metabolism of purine compounds. With a (functional) pKa of about 5.75 in blood (5.35 in urine), the reaction",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Uric acid &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;Urate- &nbsp;+ &nbsp;H+",
"   </p>",
"   <p>",
"    is shifted far to the right at the normal arterial pH of 7.40. As a result, most uric acid circulates as the urate anion.",
"   </p>",
"   <p>",
"    The vast majority of mammalian species have extremely low serum urate levels (about 1",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    60 micromol) because uric acid is converted to allantoin, a highly soluble excretory product. By contrast, uric acid is the end product of purine metabolism in humans, because the human homolog of the mammalian uricase gene is structurally modified to an unexpressed (pseudogene) state. Thus, normal humans have serum urate concentrations approaching the theoretical limit of solubility of urate in serum (6.8",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and regularly excrete urine that is supersaturated with respect to uric acid. As an example, the mean serum urate concentration is about 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    among healthy adult white men in the United States, and the prevalence of hyperuricemia in this group is estimated to be at least 5 to 8 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal adult male has a total body urate pool of approximately 1200 mg, twice that of the adult female. This gender difference may be explained by an enhancement of renal urate excretion in women of childbearing age due to the effects of estrogenic compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/1\">",
"     1",
"    </a>",
"    ], which likely reduce the number of active renal urate transporters, resulting in lesser renal tubular uric acid reabsorption and thus increased urate clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/2\">",
"     2",
"    </a>",
"    ]. Normally, all urate measured in the body pool is believed to be soluble urate. When insoluble urate crystal deposition occurs (in gout), body pool measurements underestimate the body urate pool. Under normal steady state conditions, daily turnover of about 60 percent of the urate pool is achieved by balanced production and elimination of uric acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     URIC ACID PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uric acid is not typically ingested; it is produced in the liver from the degradation of dietary and endogenously synthesized purine compounds. Dietary intake appears to provide a significant source of urate precursors, as a purine-free formula diet reduces urinary excretion of uric acid by approximately 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The urate production process (purine degradation) involves the breakdown of the purine mononucleotides, guanylic acid (GMP), inosinic acid (IMP), and adenylic acid (AMP), ultimately into the purine bases, guanine and hypoxanthine. These latter two compounds are then metabolized to xanthine. In the final step of the xanthine oxidase reaction, xanthine is irreversibly oxidized to produce uric acid (",
"    <a class=\"graphic graphic_figure graphicRef75554 \" href=\"UTD.htm?5/6/5225\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     URIC ACID EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of minor non-specific contributions from peroxidases and catalases, human tissues do not have the ability to metabolize urate. Thus, in order to maintain homeostasis, urate must be eliminated by the gut and the kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entry of urate into the intestine is most likely a passive process that varies with serum urate concentration. Intestinal tract bacteria are able to degrade uric acid. This breakdown process (intestinal uricolysis) is responsible for approximately one-third of total urate disposal, nearly all urate disposed of by extrarenal routes. Under normal conditions, uric acid is almost completely degraded by colonic bacteria, with little being found in the stool [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Urinary excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary uric acid excretion accounts for the remaining two-thirds of the daily uric acid disposal. Distinct processes involved in uric acid excretion by the kidneys were operationally defined by means of pharmacologic and physiologic studies in experimental animals and in humans. The results of these studies were consistent with a four-compartment model composed by glomerular filtration; presecretory reabsorption; secretion; and postsecretory reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/5\">",
"     5",
"    </a>",
"    ], with the last three steps occurring in the proximal tubule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15684?source=see_link&amp;anchor=H3#H3\">",
"     \"Chapter 3C: Secretory pathways in proximal tubule\", section on 'Organic anion secretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerular filtration &mdash; Urate circulates with only a small proportion (less than 5 percent) bound to serum proteins. Thus, all or nearly all urate is readily available for filtration at the glomerulus. Renal clearance of uric acid in normal adults, however, is only 7 to 12 percent of the filtered load, indicating that there is net tubular reabsorption of about 90 percent of filtered urate.",
"     </li>",
"     <li>",
"      Proximal reabsorption and secretion &mdash; Most of the filtered urate is reabsorbed in the early proximal tubule. In the four-compartment model, nearly quantitative early proximal tubular reabsorption is followed by tubular secretion in the S2 segment of the proximal tubule that returns approximately 50 percent of the filtered urate back into the tubular lumen. This secretory process is the source of most of the excreted uric acid. However, the majority of secreted urate undergoes postsecretory reabsorption that occurs predominantly in the last segment (S3) of the proximal tubule. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15684?source=see_link&amp;anchor=H3#H3\">",
"       \"Chapter 3C: Secretory pathways in proximal tubule\", section on 'Organic anion secretion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The molecular mechanisms affecting these processes remained incompletely understood until attention was redirected from the methods of classical renal physiology and pharmacology to the identification and cloning of urate transporters. Two such transporters, URAT1 and Glut9, are members of the organic acid transporter (OAT) family and have predominant effects on serum urate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A",
"    <span class=\"nowrap\">",
"     urate/organic",
"    </span>",
"    anion exchanger (URAT1) has been identified and characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The URAT1 transporter is a highly urate-specific and distinct organic anion exchanger and is encoded by SLC22A12, a gene residing on chromosome 11q13. The URAT1 protein is localized to the luminal membrane of proximal renal tubular epithelial cells but is not present on distal tubular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/6\">",
"     6",
"    </a>",
"    ] or confirmed to be elsewhere in the body in humans. Urate transport via URAT1 is independent of direct sodium-urate cotransport and is not driven by membrane potential.",
"   </p>",
"   <p>",
"    URAT1-mediated transport is, however, inhibited selectively by organic anions, including metabolites: lactate, nicotinate, acetoacetate, hydroxybutyrate, and succinate. Intracellular accumulation of organic anions, for which URAT1 has affinity, favors the reabsorption of urate in exchange for these anions, which move down their electrochemical gradients into the tubular lumen. This scheme provides a basis for the hyperuricemia associated with increased levels of these anions.",
"   </p>",
"   <p>",
"    Certain drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    , phenylbutazone, sulfinpyrazone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    , benzbromarone, and diuretics, also affect urate transport.",
"   </p>",
"   <p>",
"    Drugs or metabolites with affinity for URAT1 will be uricosuric when acting from the tubular lumen but will be uricoretentive when acting from the intracellular space, providing a basis for URAT1-mediated regulation of blood urate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/6\">",
"     6",
"    </a>",
"    ]. Mutations in SLC22A12 have been demonstrated in affected members of families with inherited renal tubular defects resulting in hypouricemia, increased excretion of urate, susceptibility to exercise-induced acute renal failure, and chronic renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7177?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypouricemia: Causes and clinical significance\", section on 'Familial renal hypouricemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the functional characteristics of URAT1 appear to explain much of the dynamics of renal tubular uric acid handling and many of the effects of drugs and metabolites on uric acid transport in the kidney, knowledge of these processes remains incomplete. URAT1 does not uniquely explain renal urate transport in either normal individuals or primary gout patients.",
"   </p>",
"   <p>",
"    First, studies of the structure and function of URAT1 in patients with primary gout have not confirmed that a major proportion of primary gout with uric acid underexcretion results from increased expression of URAT1, either as a result of structural alterations in the transporter or its gene (as with genetic polymorphisms), or from increased numbers of transporter molecules due to altered function of an effector(s) of URAT1 turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In fact, gout and hyperuricemia have been associated with a number of renal urate transporter genes in addition to SLC22A12. These include SLC2A9 (gene encoding Glut9) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/2,11,12\">",
"     2,11,12",
"    </a>",
"    ], ABCG2 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], SLC17A1 (gene encoding a sodium-phosphate cotransporter, NPT1) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/14\">",
"     14",
"    </a>",
"    ], SLC17A3 (gene encoding another sodium-phosphate cotransporter, NPT4) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/12\">",
"     12",
"    </a>",
"    ], SLC22A11 (gene encoding an organic acid transporter, OAT4) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/15\">",
"     15",
"    </a>",
"    ], and SLC16A9 (gene encoding monocarboxylic acid transporter 9, MCT9). In addition, genetic associations between serum urate level and the PDZK1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/15\">",
"     15",
"    </a>",
"    ] further support the importance of a URAT1-PDZ-NPT1 complex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/16\">",
"     16",
"    </a>",
"    ] in the control of net urate",
"    <span class=\"nowrap\">",
"     reabsorption/secretion.",
"    </span>",
"   </p>",
"   <p>",
"    Second, the finding that the fractional renal excretion of urate (FEur = uric acid",
"    <span class=\"nowrap\">",
"     clearance/creatinine",
"    </span>",
"    clearance x 100) in URAT1 knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/17\">",
"     17",
"    </a>",
"    ] remains substantially less than 1.0 suggests that mechanisms of uric acid reabsorption other than URAT1 contribute to this process.",
"   </p>",
"   <p>",
"    In support of this view, a large, well-powered human genome-wide scan revealed associations of three genes encoding renal urate transporters (SLC2A9, ABCG2, and SLC17A3) other than SLC22A12 with serum urate concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/12\">",
"     12",
"    </a>",
"    ]. Of these urate transporter genes, SLC2A9 has the strongest effect on serum urate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The product of the SLC2A9 gene on chromosome 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/7,11\">",
"     7,11",
"    </a>",
"    ] is glucose transporter 9 (GLUT9), a voltage-driven urate efflux transporter that mediates urate reabsorption from the tubular cell to the circulation. In man, GLUT9 exists in two isoforms: GLUT9L, identified on the basolateral aspect of the proximal renal tubular epithelial cell, and GLUT9S on the apical surface [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/7,18,19\">",
"     7,18,19",
"    </a>",
"    ]. As with URAT1, the reabsorption of urate by GLUT9 is inhibited by the uricosuric agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    and benzbromarone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GLUT9, when expressed in Xenopus laevis oocytes, has strong uric acid transporting ability [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/19\">",
"     19",
"    </a>",
"    ] and has, in fact, previously been identified as a fructose transporter. It is possible that this finding may contribute to an understanding of the associations of hyperuricemia, gout, and components of the metabolic syndrome with diets rich in high fructose-containing corn syrup [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A substantial role for SLC2A9 in the physiological regulation of serum or plasma urate levels is further suggested by the results of genome-wide association and genotyping studies confirming that the SLC2A9 locus and certain polymorphisms in SLC2A9 are associated with an increased risk for hyperuricemia and gout [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/2,11,12\">",
"     2,11,12",
"    </a>",
"    ]. Mutations of GLUT9 have also been linked with renal hypouricemia, in patients with intact URAT1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two other genes that have been identified by a genome-wide association study, ABCG2 and SLC17A3 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/12\">",
"     12",
"    </a>",
"    ], encode proximal tubular epithelium luminal surface urate transporters involved in urate efflux (luminal secretion). Each of these genes has common variants that are associated with serum urate elevation and with an increased risk of gout [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/12\">",
"     12",
"    </a>",
"    ]. The apical membrane protein product of the ABCG2 gene is known to transport purine nucleoside analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The other gene (SLC17A3) encodes a protein (NPT4) that is homologous to a rat",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    transporter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional candidate for a voltage-sensitive human urate transporter is a protein (hUAT1 or galectin 9) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/27\">",
"     27",
"    </a>",
"    ] that is a highly selective urate ion channel when inserted in lipid bilayers. The gene for hUAT1 maps to chromosome 17, and at least three isoforms of hUAT1 have been identified. The authenticity of hUAT1 as a renal urate transporter or channel in vivo, however, remains in doubt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/5\">",
"     5",
"    </a>",
"    ] because hUAT1 is structurally atypical for a transporter, is broadly tissue distributed, and has apparently unrelated functions previously ascribed to galectin 9 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/27\">",
"     27",
"    </a>",
"    ]. It is possible, however, that one of the less well-characterized isoforms of hUAT1 is a voltage-sensitive urate channel involved in tubular urate transport. Additional renal transporters accepting urate have been identified and may play roles in urinary uric acid excretion as well [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/17,28\">",
"     17,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HYPERURICEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased efficiency of renal uric acid excretion is responsible for about 85 to 90 percent of primary or secondary hyperuricemia (",
"    <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/29\">",
"     29",
"    </a>",
"    ]. This observation is not surprising based on the complexity of renal uric acid handling and the sensitivity of the kidney to endogenous metabolites, alterations in volume status, and drugs. Volume depletion due to diuretics, for example, is a common cause of hyperuricemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"     \"Diuretic-induced hyperuricemia and gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to appreciate, however, that \"under-excretors\" actually have normal rates of urinary uric acid excretion since this is required to maintain the steady state in which urate production and disposal are relatively equal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H838162389#H838162389\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'The steady state'",
"    </a>",
"    .) It is the reduced efficiency of urate excretion that obligates a higher serum urate concentration in order to achieve the necessary rate of urinary uric acid excretion.",
"   </p>",
"   <p>",
"    The remaining 10 to 15 percent of patients with hyperuricemia overproduce uric acid. These disorders are typically due to inherited defects in regulation of purine nucleotide synthesis, disordered ATP metabolism, or disorders resulting in increased rates of cell turnover. However, even among those whose daily excretion of uric acid is higher than normal, decreased efficiency of renal uric acid excretion may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HYPOURICEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar pathogenetic considerations apply to hypouricemia. This biochemical aberration can be induced by decreased production (primarily due to rare enzyme defects) or to increased urinary excretion. The latter can result from a genetic defect in the urate-organic anion countertransporter URAT1 in the proximal tubule (encoded by the SLC22A12 gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/6,8\">",
"     6,8",
"    </a>",
"    ], a loss of function genetic defect in the high-capacity renal urate transporter GLUT9 (encoded by SLC2A9) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24230/abstract/18\">",
"     18",
"    </a>",
"    ], the Fanconi syndrome, with volume expansion in the syndrome of inappropriate ADH secretion, in some malignancies (especially Hodgkin lymphoma), and in the syndrome of cerebral salt wasting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7177?source=see_link\">",
"     \"Hypouricemia: Causes and clinical significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68800977\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uric acid is the end product of the metabolism of purine compounds. With a (functional) pKa of about 5.75 in blood (5.35 in urine), the reaction, uric&nbsp;acid&nbsp;&nbsp;&lt;&gt;&nbsp;urate&nbsp;&nbsp;+&nbsp;&nbsp;H+, is shifted far to the right at the normal arterial pH of 7.40. As a result, most uric acid circulates as the urate anion. Normal humans have serum urate concentrations approaching the theoretical limit of solubility of urate in serum (6.8",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      and regularly excrete urine that is supersaturated with respect to uric acid. Normal adult males have a total body urate pool that averages approximately 1200 mg, nearly twice that of adult females. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uric acid is produced in the liver from the degradation of dietary and endogenously synthesized purine compounds. Uric acid is not typically ingested, although dietary intake provides a significant source of urate precursors. Urate production involves the breakdown of the purine mononucleotides, guanylic acid, inosinic acid, and adenylic acid, ultimately into the purine bases, guanine and hypoxanthine. These latter two compounds are then metabolized to xanthine, which is irreversibly oxidized by xanthine oxidase to produce uric acid (",
"      <a class=\"graphic graphic_figure graphicRef75554 \" href=\"UTD.htm?5/6/5225\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Uric acid production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human tissues have a very limited ability to metabolize urate, which must be eliminated by the gut and the kidney to maintain homeostasis. The entry of urate into the intestine is most likely a passive process that varies with serum urate concentration. Intestinal tract bacteria degrade uric acid. This process (intestinal uricolysis) is responsible for approximately one-third of total urate disposal. Urinary uric acid excretion accounts for the remaining two-thirds of the daily uric acid disposal. Classical methods of renal physiology identified four processes involved in uric acid excretion by the kidneys, including glomerular filtration, presecretory reabsorption, secretion, and postsecretory reabsorption, with the last three steps occurring in the proximal tubule.",
"      <br/>",
"      <br/>",
"      Subsequent molecular genetic and physiologic studies of urate transport have identified multiple renal urate transporters operating in the proximal renal tubule and have established polymorphisms in the genes encoding several of these transporters, as well as effects of pharmacological agents that may underlie disordered uric acid balance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Uric acid excretion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Gastrointestinal tract'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Urinary excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased efficiency of renal uric acid excretion is responsible for about 85 to 90 percent of primary or secondary hyperuricemia (",
"      <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"       table 1",
"      </a>",
"      ). This results from a reduced efficiency of urate excretion that obligates a higher serum urate concentration in order to achieve the necessary rate of urinary uric acid excretion. &ldquo;Under-excretors&rdquo; actually have normal rates of urinary uric acid excretion since this is required to maintain the steady state in which urate production and disposal are relatively equal. The remaining 10 to 15 percent of patients with hyperuricemia overproduce uric acid, which is typically due to inherited defects in regulation of purine nucleotide synthesis, disordered ATP metabolism, or disorders resulting in increased rates of cell turnover. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hyperuricemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypouricemia can be induced by decreased production (primarily due to rare enzyme defects) or to increased urinary excretion of uric acid. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypouricemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/1\">",
"      Ant&oacute;n FM, Garc&iacute;a Puig J, Ramos T, et al. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism 1986; 35:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/2\">",
"      D&ouml;ring A, Gieger C, Mehta D, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008; 40:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/3\">",
"      Griebsch A, Z&ouml;llner N. Effect of ribomononucleotides given orally on uric acid production in man. Adv Exp Med Biol 1974; 41:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/4\">",
"      Sorensen LB. The elimination of uric acid in man. Scand J Clin Lab Invest 1960; 12 (supplement 54):1.",
"     </a>",
"    </li>",
"    <li>",
"     Roch-Ramel F, Diezi J. Renal transport of organic ions and uric acid. In: Diseases of the Kidney, 6th, Schrier RW, Gottschalk CE (Eds), Little, Brown, Boston 1996. p.231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/6\">",
"      Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/7\">",
"      Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5:e197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/8\">",
"      Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/9\">",
"      Taniguchi A, Urano W, Yamanaka M, et al. A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Arthritis Rheum 2005; 52:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/10\">",
"      Shima Y, Teruya K, Ohta H. Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. Life Sci 2006; 79:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/11\">",
"      Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/12\">",
"      Dehghan A, K&ouml;ttgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008; 372:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/13\">",
"      Woodward OM, K&ouml;ttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 2009; 106:10338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/14\">",
"      Urano W, Taniguchi A, Anzai N, et al. Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis 2010; 69:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/15\">",
"      Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5:e1000504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/16\">",
"      Endou H, Anzai N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids 2008; 27:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/17\">",
"      Eraly SA, Vallon V, Rieg T, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 2008; 33:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/18\">",
"      Matsuo H, Chiba T, Nagamori S, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 2008; 83:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/19\">",
"      Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283:26834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/20\">",
"      Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005; 1:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/21\">",
"      Gao X, Qi L, Qiao N, et al. Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. Hypertension 2007; 50:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/22\">",
"      Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/23\">",
"      Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/24\">",
"      Huls M, Brown CD, Windass AS, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2008; 73:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/25\">",
"      Takenaka K, Morgan JA, Scheffer GL, et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 2007; 67:6965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/26\">",
"      Ishibashi K, Matsuzaki T, Takata K, Imai M. Identification of a new member of type I Na/phosphate co-transporter in the rat kidney. Nephron Physiol 2003; 94:p10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/27\">",
"      Lipkowitz MS, Leal-Pinto E, Rappoport JZ, et al. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 2001; 107:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/28\">",
"      Choi HK, Mount DB, Reginato AM, et al. Pathogenesis of gout. Ann Intern Med 2005; 143:499.",
"     </a>",
"    </li>",
"    <li>",
"     Wyngaarden JB, Kelley WN. Gout and Hyperuricemia, Grune and Stratton, New York 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24230/abstract/30\">",
"      Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47:610.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1670 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24230=[""].join("\n");
var outline_f23_42_24230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H68800977\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      URIC ACID PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      URIC ACID EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Urinary excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HYPERURICEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HYPOURICEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68800977\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1670|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/6/5225\" title=\"figure 1\">",
"      Purine interconversion and degradation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1670|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/14/44267\" title=\"table 1\">",
"      Secondary uricemia excretion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15684?source=related_link\">",
"      Chapter 3C: Secretory pathways in proximal tubule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7177?source=related_link\">",
"      Hypouricemia: Causes and clinical significance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_42_24231="Sulindac: Pediatric drug information";
var content_f23_42_24231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulindac: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"    see \"Sulindac: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/30/29157?source=see_link\">",
"    see \"Sulindac: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clinoril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sulin&reg;;",
"     </li>",
"     <li>",
"      Novo-Sundac;",
"     </li>",
"     <li>",
"      Nu-Sulindac;",
"     </li>",
"     <li>",
"      Nu-Sundac;",
"     </li>",
"     <li>",
"      Teva-Sulindac",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"      see \"Sulindac: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Limited information exists; some centers use the following: 2-4 mg/kg/day in 2 divided doses; maximum: 6 mg/kg/day; do not exceed 400 mg/day (Giannini, 1995; Skeith, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 150-200 mg twice daily; not to exceed 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Not recommended with advanced renal impairment; if required, decrease dose and monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Dose reduction is necessary; discontinue if abnormal liver function tests occur.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 150 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clinoril&reg;: 200 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088573.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088573.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or milk to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F11330085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) in tightly closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of inflammatory diseases including osteoarthritis, rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, and acute painful shoulder (acute subacromial bursitis/supraspinatus tendonitis) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F224232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Clinoril&reg; may be confused with Cleocin&reg;, Clozaril&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F224230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, flatulence, GI pain, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, ageusia, alopecia, anaphylaxis, angioneurotic edema, aplastic anemia, arrhythmia, aseptic meningitis, bitter taste, blurred vision, bone marrow depression, bronchial spasm, bruising, CHF, cholestasis, colitis, conjunctivitis, crystalluria, depression, dry mucous membranes, dyspnea, dysuria, epistaxis, erythema multiforme, exfoliative dermatitis, fever, gastritis, GI bleeding, GI perforation, glossitis, gynecomastia, hearing decreased, hematuria, hemolytic anemia, hepatitis, hepatic failure, hyperglycemia, hyperkalemia, hypersensitivity reaction, hypersensitivity syndrome (includes chills, diaphoresis, fever, flushing), hypersensitivity vasculitis, hypertension, insomnia, intestinal stricture, interstitial nephritis, jaundice, leukopenia, liver function abnormal, metallic taste, necrotizing fascitis, nephrotic syndrome, neuritis, neutropenia, palpitation, pancreatitis, paresthesia, peptic ulcer, photosensitivity, proteinuria, psychosis, purpura, renal calculi, renal failure, renal impairment, retinal disturbances, seizure, somnolence, Stevens-Johnson syndrome, stomatitis, syncope, thrombocytopenia, toxic epidermal necrolysis, urine discoloration, urticaria, vaginal bleeding, vertigo, visual disturbance, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulindac or any component; history of asthma, urticaria, or allergic-type reaction to aspirin, or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with peptic ulcer disease, GI bleeding, bleeding abnormalities, impaired renal or hepatic function, CHF, hypertension, and patients receiving anticoagulants",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may increase the risk of GI inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, or those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury. Use caution in patients with renal lithiasis; sulindac metabolites have been reported as components of renal stones; use hydration in patients with a history of renal stones. Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop or if systemic manifestations occur. May require dosage adjustment in hepatic dysfunction; sulfide and sulfone metabolites may accumulate. Pancreatitis has been reported; discontinue with suspected pancreatitis. May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the \"aspirin triad\" who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimethyl Sulfoxide: May decrease the metabolism of Sulindac. Specifically, the concentrations of the active sulfide metabolite are decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease rate and extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1620784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies sulindac as pregnancy category C. Sulindac and the sulfide metabolite have been found to cross the placenta. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID in the first trimester may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, failure of the ductus arteriosus to close postnatally, and fetal tricuspid regurgitation; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding, platelet dysfunction with resultant bleeding; or pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31-32 weeks gestation is not recommended by some clinicians). Sulindac has been used in the management of preterm labor. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including sulindac. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at (877) 311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver enzymes, BUN, serum creatinine, CBC with differential, platelet count; periodic ophthalmologic exams with chronic use",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11330086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Crosses blood-brain barrier (brain concentrations &lt;4% of plasma concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Sulindac: 93%, sulfone metabolite: 95%, sulfide metabolite: 98%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; prodrug metabolized to sulfide metabolite (active) for therapeutic effects and to sulfone metabolites (inactive); parent and inactive sulfone metabolite undergo extensive enterohepatic recirculation; metabolites undergo glucuronide conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Sulindac: ~8 hours; sulfide metabolite: ~16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Sulindac: 3-4 hours; sulfide and sulfone metabolites: 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine (~50%, primarily as inactive metabolites, &lt;1% as active metabolite); feces (~25%, primarily as metabolites);",
"     <b>",
"      Note:",
"     </b>",
"     Metabolites appear principally as glucuronide conjugates in urine and bile.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/30/29157?source=see_link\">",
"      see \"Sulindac: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulindac is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of sulindac.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Sulindac may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; palpitations or weight gain.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Giannini EH and Cawkwell GD, &ldquo;Drug Treatment in Children With Juvenile Rheumatoid Arthritis. Past, Present, and Future,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1995, 42(5):1099-125.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/42/24231/abstract-text/7567188 /pubmed\" id=\"7567188 \" target=\"_blank\">",
"        7567188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skeith KJ and Jamali F, &ldquo;Clinical Pharmacokinetics of Drugs Used in Juvenile Arthritis,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 21(2):129-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/42/24231/abstract-text/1884567/pubmed\" id=\"1884567\" target=\"_blank\">",
"        1884567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12820 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24231=[""].join("\n");
var outline_f23_42_24231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709422\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224183\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224184\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055560\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055554\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224160\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224145\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874833\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055564\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11330085\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055563\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224232\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224230\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055566\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055553\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055552\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300100\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224154\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055568\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224156\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1620784\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055559\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055551\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11330086\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055558\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=related_link\">",
"      Sulindac: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/30/29157?source=related_link\">",
"      Sulindac: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_42_24232="Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology";
var content_f23_42_24232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/42/24232/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/42/24232/contributors\">",
"     Robert L DuPont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/42/24232/contributors\">",
"     William Greene, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/42/24232/contributors\">",
"     R Bruce Lydiard, PhD, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/42/24232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/42/24232/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/42/24232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/42/24232/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/42/24232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"sedative-hypnotics\" refers to a heterogeneous class of drugs that includes benzodiazepines, barbiturates, and various other hypnotics. A sedative lowers excitement and calms the awake patient, whereas a hypnotic produces drowsiness and promotes sleep. By tradition, they are categorized into a single class because of their common ability to induce sedation and sleep.",
"   </p>",
"   <p>",
"    Significant variation in safety, and in the circumstances for which use is clinically appropriate, exists within the class of sedative- hypnotics. Barbiturates are now largely limited to induction of anesthesia, while benzodiazepines are widely used for purposes other than sedation, including the treatment of anxiety, insomnia, and epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several properties distinguish the benzodiazepines from the other sedatives. Although the clinical effects of the benzodiazepines resemble and overlap with other sedative-hypnotics, benzodiazepines are more specifically anxiolytic. They do not produce surgical anesthesia, coma, or death, even at high doses, except when co-administered with other agents that suppress respiration.",
"   </p>",
"   <p>",
"    The relative safety and effectiveness of the benzodiazepines create a significant margin of safety that has led to their widespread use [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/2\">",
"     2",
"    </a>",
"    ]. Several of the benzodiazepines, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    (Xanax),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    (Valium),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (Ativan), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    (Klonopin) are among the most frequently prescribed psychotropic medicines worldwide. The World Health Organization [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/3\">",
"     3",
"    </a>",
"    ] labeled them \"essential drugs\" that should be available in all countries for medical purposes.",
"   </p>",
"   <p>",
"    Despite their relative safety, issues related to potential abuse, withdrawal, and side effects of benzodiazepines remain. In March of 2007, the United States Food and Drug Administration advised that the manufacturers of sedative-hypnotic medications strengthen their labeling to include stronger language about rare cases of severe allergic reactions and complex sleep-related behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians must learn to distinguish between patients who use benzodiazepines safely, even over long periods of time, and patients who use benzodiazepines as part of a pattern of drug or alcohol abuse.",
"   </p>",
"   <p>",
"    The use of sedatives and hypnotics for the treatment of anxiety and insomnia in patients with addiction to alcohol and other drugs entails additional risks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the pharmacology and pharmacoepidemiology of sedative and hypnotic medications. The medical and non-medical use of these drugs is discussed separately, as is treatment of specific medical conditions for which these drugs are indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL CONTEXT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barbital was introduced into medical practice in 1903, and phenobarbital in 1912. Their rapid success led to the development of over 2,000 derivatives of barbituric acid, with dozens being used in medical practice. The only non-opiate sedatives to precede the barbiturates were the bromides and chloral hydrate, both in widespread use before the end of the nineteenth century.",
"   </p>",
"   <p>",
"    Benzodiazepines were first recognized in the 1950s for their ability to produce \"taming\" without apparent sedation in animal experiments. Chlordiazepoxide (Librium), the first benzodiazepine used in clinical practice, was introduced in 1961. More than 3,000 additional benzodiazepines have since been synthesized, of which about 50 have been used clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benzodiazepines were recognized as comparatively problem-free compared to the barbiturates, and rapidly replaced earlier sedatives. Their popularity reached unprecedented levels in the early 1970s. A powerful backlash emerged, related to \"social issues,\" resulting in a decline in the use of benzodiazepines during the 1980s despite a rise in the prevalence of the disorders for which they are used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emergence of various regulatory approaches to limit use of benzodiazepines in medical practice led to the danger that clinicians would revert to prescribing the older, more toxic sedatives and hypnotics, as occurred among Medicaid recipients in New York [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Thus, there is more than historical interest in reviewing the earlier sedatives, because they are new medicines for some younger medical practitioners.",
"   </p>",
"   <p>",
"    Most benzodiazepines are off patent currently, and are not actively promoted by pharmaceutical representatives. Lack of their promotion has been associated with a reduction in the public and professional controversy over the use of the benzodiazepines in recent years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sedatives and hypnotics will be considered, for convenience, in four groups: barbiturates, \"other sedatives and hypnotics,\" benzodiazepines, and benzodiazepine-related hypnotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used barbiturates today are amobarbital (Amytal), butabarbital (Butisol), mephobarbital (Mebaral), pentobarbital (Nembutal), secobarbital (Seconal), butalbital",
"    <span class=\"nowrap\">",
"     (Fioricet/Firoinal),",
"    </span>",
"    and phenobarbital (Luminal). The first six have an intermediate duration of action, whereas the last, phenobarbital, has a long duration of action. Short-acting barbiturates are used as anesthetics, but not in outpatient medicine.",
"   </p>",
"   <p>",
"    Barbiturates reversibly suppress the activity of all excitable tissue, including central nervous system (CNS) activity, along a dose-dependent continuum. Effects on the CNS begin with calming and progress to sleep, unconsciousness, coma, surgical anesthesia, and, ultimately, fatal respiratory and cardiovascular depression. At lower doses, sedatives can cause impaired cognitive and motor functioning (including staggering and slurred speech).",
"   </p>",
"   <p>",
"    The therapeutic index for the sedative effects of the barbiturates is low, with general CNS depression linked to the desired therapeutic effects. Fatal overdose can occur with doses that can be achieved within the usual number of pills dispensed in a single prescription.",
"   </p>",
"   <p>",
"    The barbiturates affect the gamma-aminobutyric acid (GABA) system, producing both a cross-tolerance to other sedating drugs (including alcohol and the benzodiazepines), and a heightened risk of fatal overdose reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/2\">",
"     2",
"    </a>",
"    ]. Rapid development of tolerance for both sedation and hypnosis is a common problem, resulting in a tendency for medical patients to raise the dose with chronic administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other sedatives and hypnotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several diverse sedative hypnotic medicines were developed through the twentieth century that are no longer in use, due to their profound CNS depression, low therapeutic index, high abuse potential, and little or no analgesic properties. These include chloral hydrate (Noctec), ethchlorvynol (Placidyl), ethinamate (Valmid), glutethimide (Doriden), meprobamate (Miltown, Equanil), methyprylon (Noludar), and paraldehyde (Paral); they have no useful place in contemporary medical practice.",
"   </p>",
"   <p>",
"    Other medications have been used for management of insomnia, including antihistamines, sedating antidepressants, melatonin and melatonin agonists. These medications and treatment of insomnia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In recent years, a variety of alternatives to the benzodiazepines have become available to treat both anxiety and insomnia. Buspirone (Buspar) has been shown to reduce anxiety in generalized anxiety disorder. Buspirone is not abused by alcoholics and drug addicts, and it does not produce withdrawal symptoms on abrupt discontinuation. Buspirone requires several weeks of daily dosing to produce anxiolytic effects. Approved use in the US is limited to generalized anxiety disorder and its anxiolytic effects may be less apparent to patients than those produced by the benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines exert their principal pharmacodynamic effect via CNS GABA receptors, potentiating the effects of endogenous GABA, the main inhibitory neurotransmitter. GABA receptors are membrane-bound proteins divided into three subtypes, GABAA, GABAB, and GABAC receptors. The GABAA receptors are composed of five subunits that together form the chloride channel, which primarily mediates neuronal excitability (seizures), rapid mood changes, clinical anxiety, and sleep. GABAB receptors mediate memory, mood, and analgesia. The role of the GABAC receptors remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/12\">",
"     12",
"    </a>",
"    ]. Flumazenil, a benzodiazepine antagonist, interacts with GABAA receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/13\">",
"     13",
"    </a>",
"    ] and is used clinically to rapidly reverse the effects of benzodiazepine overdoses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benzodiazepines may also produce clinically relevant effects by mechanisms that do not involve GABA-mediated chloride conductance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/14\">",
"     14",
"    </a>",
"    ]. The benzodiazepines have only a slight effect on rapid eye movement (REM) sleep, but suppress deeper, stage 4 sleep. Although this effect is probably of no clinical significance in most settings,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    has been used to prevent \"night terrors\" that arise in stage 4 sleep.",
"   </p>",
"   <p>",
"    Although they share many class effects, unique properties of individual benzodiazepines have clinical significance. These pharmacologic differences among the benzodiazepines include the rapidity of onset (distributional half-life), persistence of active drug",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metabolite in the body (elimination half-life), major metabolic breakdown pathways (conjugation versus oxidation), and specific molecular structure (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    has a unique triazolo ring that may account for some difference in its clinical effects) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/2\">",
"     2",
"    </a>",
"    ]. These differences are summarized in a table for the most widely used benzodiazepines, along with clinically important pharmacological characteristics related to the use and abuse of the benzodiazepines (",
"    <a class=\"graphic graphic_table graphicRef65653 \" href=\"UTD.htm?39/16/40205\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Speed of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important distinction among the benzodiazepines, in the context of abuse potential, is the speed of onset [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/16\">",
"     16",
"    </a>",
"    ]. Drugs that more rapidly reach peak brain levels after oral administration are relatively more likely to produce brain reward or euphoria, and are therefore more likely to be abused. Benzodiazepines with a slow onset (because they are either slowly absorbed or must be metabolized to produce an active substance) have a relatively lower abuse potential.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    has a relatively rapid onset of action and is therefore among the most effective producers of euphoria. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=see_link\">",
"     clorazepate",
"    </a>",
"    (Tranxene) and prazepam (Centrax), with inactive parent compounds, are less likely to be abused.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     Oxazepam",
"    </a>",
"    (Serax) and the other slower onset benzodiazepines also appear to have relatively low abuse potentials.",
"   </p>",
"   <p>",
"    The concept that speed of onset affects abuse potential has been challenged, however. Some believe that abuse is solely related to equivalent dosage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/17\">",
"     17",
"    </a>",
"    ]. Other researchers attribute the greater abuse potential for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    both to their more rapid absorption and penetration of the blood-brain barrier due to greater lipid solubility [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been a recent interest in the development of new delivery mechanisms for the two most widely used benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     Alprazolam",
"    </a>",
"    is now available in an extended release formulation, Xanax XR. It has the advantage of slower onset of action, which reduces initial sedation in the hour or two after administration. Slower onset of action also lowers the abuse potential of Xanax XR, since it is the rapid onset of action that triggers the brain reward that addicts seek. This new formulation of alprazolam permits once-a-day, or at most BID, dosing and reduces the risk of \"clock watching\", which may be seen with frequent dosing throughout the day.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    has been reformulated into an orally disintegrating tablet for easy administration without swallowing a pill.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines that are metabolized by cytochrome P450 oxidation in the liver may alter the effects of other drugs. This is illustrated by the \"boosting\" effect of some benzodiazepines when used by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    -maintained patients. Methadone and various benzodiazepines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"     triazolam",
"    </a>",
"    ) are substrates of the 3A4 enzyme. Simultaneous use of a benzodiazepine that competes with methadone for oxidative pathways in the liver produces higher peak levels of methadone in the blood (and brain) shortly after methadone is administered.",
"   </p>",
"   <p>",
"    Benzodiazepines metabolized primarily via conjugation (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    ) are cleared largely by the kidneys and are less dependent on liver functioning. These medications have fewer P450 interactions and are better choices for patients taking multiple medications and for patients with compromised liver function, including alcohol abusers and the elderly.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     Oxazepam",
"    </a>",
"    is both a slow-onset and a conjugated benzodiazepine, making it perhaps the best choice for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    -maintained patients who are treated with a benzodiazepine. Oxazepam has a short elimination half-life, and must be taken three or four times a day for continuous therapeutic effects. However, oxazepam is as likely to produce physical dependence (including difficulties on discontinuation) as any other benzodiazepine, and is commonly abused in Europe, where it is used more widely than in the US. Thus, whatever theoretical benefit oxazepam may possess for alcohol and drug abusers compared to other benzodiazepines is relative and not absolute [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/8\">",
"     8",
"    </a>",
"    ]. This observation also suggests that whatever benzodiazepine is most widely available is likely to be the one most often abused in any community, regardless of its particular pharmacokinetics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Persistence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistence of a benzodiazepine (or an active metabolite) in the body governs the tempo of withdrawal onset in patients who have used benzodiazepines everyday for prolonged periods. Benzodiazepines with shorter elimination half-lives are more likely to produce acute withdrawal on abrupt cessation after prolonged use. In contrast, those with longer elimination half-lives usually produce more delayed and somewhat attenuated withdrawal symptoms. In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    are more rapidly eliminated than are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=see_link\">",
"     clorazepate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/3/27703?source=see_link\">",
"     flurazepam",
"    </a>",
"    , and prazepam.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    has a longer elimination half-life than alprazolam or lorazepam, so it is more appealing as a therapeutic agent in the treatment of withdrawal.",
"   </p>",
"   <p>",
"    Abrupt discontinuation is not appropriate for benzodiazepine discontinuation after prolonged daily use, especially when high doses are used. Short-acting benzodiazepines, when withdrawn gradually over several weeks or longer, do not produce more withdrawal symptoms than longer acting benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A long half-life may reduce the speed of onset and severity of benzodiazepine withdrawal on abrupt discontinuation, but can be problematic in other situations. Use of long half-life, but not shorter half-life, benzodiazepines was associated with an increase in motor vehicle crashes in elderly persons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Reinforcement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reinforcement is the potential for medicines to be abused or \"liked\" by alcoholics and drug abusers. In controlled studies, benzodiazepines are not reinforcing or \"liked\" by subjects without a prior history of abuse of alcohol or other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/16\">",
"     16",
"    </a>",
"    ]. For example, normal and anxious subjects, given a choice between placebo and benzodiazepines, more often choose the placebo in double-blind acute dose experiments, regardless of the specific benzodiazepine given [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, subjects with a history of addiction in double-blind studies prefer benzodiazepines, especially at high doses, to placebo.",
"   </p>",
"   <p>",
"    Even for subjects with a history of substance abuse, the benzodiazepines are relatively weak reinforcers compared to other drugs. People with a history of addiction show a greater preference for intermediate-acting barbiturates and stimulants, as well as narcotics, than for benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/16\">",
"     16",
"    </a>",
"    ]. This research confirms the common clinical observation that benzodiazepines are rarely drugs of choice for their euphoric effects among addicted people [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/8,23\">",
"     8,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, physicians working with patients addicted to alcohol and other drugs do commonly see patients who abuse benzodiazepines, and some of these patients use benzodiazepines as their primary drug of abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;All medicines that influence the GABA system show cross-tolerance and similar withdrawal patterns. The",
"    <span class=\"nowrap\">",
"     sedative/hypnotics",
"    </span>",
"    withdrawal syndrome includes the potential for withdrawal seizures and status epilepticus on abrupt discontinuation. These medications are potent antiepileptics that raise the seizure threshold. When abruptly discontinued, they produce a rebound drop in the seizure threshold that may cause seizures even in patients without a history of prior seizures.",
"   </p>",
"   <p>",
"    Other symptoms of withdrawal include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased body temperature",
"     </li>",
"     <li>",
"      Elevated blood pressure",
"     </li>",
"     <li>",
"      Increased respiratory rate and heart rate",
"     </li>",
"     <li>",
"      Aroused level of consciousness or frank delirium",
"     </li>",
"     <li>",
"      Tremulousness",
"     </li>",
"     <li>",
"      Increased reflexes",
"     </li>",
"     <li>",
"      Disorientation",
"     </li>",
"     <li>",
"      Psychotic behavior including hallucinations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of withdrawal is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"     \"Benzodiazepine poisoning and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &nbsp;Tolerance &mdash; Tolerance develops rapidly, and is all but complete to the sedative and euphoric effects of the benzodiazepines on repeated oral administration at a steady dose for even a few days. The rapid development of tolerance for both sedation and",
"    <span class=\"nowrap\">",
"     euphoria/reward",
"    </span>",
"    is seen clinically when these medicines are used to treat anxiety. Initial sedation or drowsiness often disappears within a few days of steady dosing.",
"   </p>",
"   <p>",
"    Tolerance to the anxiolytic effects of benzodiazepines, in contrast, is practically nonexistent. Non-addicted medical patients who use a benzodiazepine to treat chronic anxiety obtain beneficial effects at constant, standard, low doses.",
"   </p>",
"   <p>",
"    The distinction between the rapid tolerance to the sedating and the euphoric effects and the absence of tolerance to the anxiolytic effects of benzodiazepines is important for the clinician. Patients who use benzodiazepines to induce euphoria (\"get high\") typically add other substances",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    escalate their benzodiazepine dose over time, reflecting tolerance to the euphoric effects of benzodiazepines among addicted people. In clear contrast, patients without a prior history of addiction who use benzodiazepines for anxiety or insomnia rarely escalate their dose even during treatment that lasts for decades. There is evidence that patients with panic disorder are more likely to decrease their dose, or maintain it, than increase the dose of benzodiazepines over time [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Benzodiazepine-related hypnotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three newer non-benzodiazepine hypnotic agents have been developed and FDA-approved for the treatment of insomnia. Zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta) are rapid-onset, short duration of action drugs that act on GABAA receptors. Their mechanism of action is not completely understood, but they can be conceptualized as benzodiazepine receptor agonists. This new generation of drugs may offer advantages over benzodiazepines in terms of safety (less tolerance and dependence) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/25\">",
"     25",
"    </a>",
"    ]. They have largely replaced the benzodiazepines as hypnotic medicines of choice, although they lack the anxiolytic, anticonvulsant, and muscle-relaxant properties of the benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All three of these agents impair memory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    performance of complex tasks in ways that are similar to benzodiazepines. They do not affect stage 4 sleep, as do the benzodiazepines. Zolpidem and zaleplon are reinforcing to alcoholics and drug addicts, underscoring the fact that the abuse potential of these drugs appears to be similar to that of benzodiazepines. Case reports of zolpidem and zaleplon abuse have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Zolpidem has a half-life of about two hours, which is consistent with therapeutic activity over a typical eight hours of sleep. Zaleplon has a one hour half-life that offers the possibility of dosing in the middle of the night for broken sleep. For this reason zaleplon is approved for use both at bedtime and in midsleep periods of insomnia. Eszopiclone has a half-life of five hours, appears to have relatively low abuse potential, and is approved for long-term use [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHARMACOEPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety disorders are the most prevalent class of mental disorders in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/30\">",
"     30",
"    </a>",
"    ]. The National Comorbidity Survey (NCS) found that between 1990 and 1992, 17.2 percent of the population had an anxiety disorder in the previous 12 months, and 24.9 percent had a lifetime history of anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The number of office visits with a recorded anxiety disorder diagnosis increased from 9.5 million in 1985, to 11.2 million per year in 1993 to 1994 and 12.3 million per year in 1997 to 1998, accounting for 1.9, 1.6, and 1.5 percent of all office visits in those years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/33\">",
"     33",
"    </a>",
"    ]. Twice as many women as men have anxiety disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonmedical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US federal government has tracked the rates of self-reported, non-medical (eg, non-therapeutic) use of a variety of drugs within the United States for more than three decades. The National Household Survey on Drug Abuse (NHSDA) separately tracks the use of \"tranquilizers\" and \"sedatives\" for people &ge;12 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/35\">",
"     35",
"    </a>",
"    ], while the Monitoring the Future (MTF) survey tracks \"tranquilizers\" and \"barbiturates\" in high school seniors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/36\">",
"     36",
"    </a>",
"    ]. Neither survey identifies \"benzodiazepines\" specifically.",
"   </p>",
"   <p>",
"    Trends over this extended period of time show an initial steady rise in nonmedical use, peaking in the late 1970s. There was a subsequent decline, reaching a low point in the early 1990s, with an upturn through 2002, and leveling off into 2006. In 2005, the NHSDA reported 2.2 percent of Americans 12 years and older had used a \"tranquilizer\" nonmedically in the prior year, compared to 4.9 percent who used opiate analgesics for nonmedical purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/36\">",
"     36",
"    </a>",
"    ]. Most who had used a benzodiazepine nonmedically had done so only a few times in their lifetime. Nonmedical use is far less common than medical use of benzodiazepines, but is nonetheless part of the problem of nonmedical use of prescribed controlled substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Medical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of US national surveys tracking medical use of the benzodiazepines showed that use peaked in 1976 and declined by about 25 percent into the late 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/8\">",
"     8",
"    </a>",
"    ]. A 1979 US survey of medical use of the benzodiazepines, near peak utilization, showed that 1.6 percent of the adult population had used a benzodiazepine on a daily basis for 12 months or longer, 9.5 percent had used benzodiazepine either less often or for shorter term, and almost 90 percent had not used a benzodiazepine. The long-term user group was two-thirds female; 71 percent were age 50 or older, and most had chronic medical problems as well as anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/8\">",
"     8",
"    </a>",
"    ]. A community-based population of older US adults (&ge;65 years) followed from 1987 to 2002 found that 5.5 percent of men and 9.8 percent of women were using benzodiazepines at baseline; 50 percent of users in the age group 65 to 74 years continued regular use of benzodiazepine at followup in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some researchers propose that benzodiazepines may be under-prescribed, rather than over-prescribed, because of the reluctance of both physician and patients to use these medicines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/38\">",
"     38",
"    </a>",
"    ]. The 1.6 percent of the population who are chronic benzodiazepine users can be compared to the 17 percent of the population suffering from anxiety disorders during a 12 month period. Three-fourths of those with anxiety disorder were receiving no treatment at all [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large US population surveys funded by the Agency for Healthcare Research and Quality showed that outpatient treatment for anxiety disorders nearly doubled between 1987 and 1999, but remained extremely low (from 0.43 to 0.83 per 100) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/42/24232/abstract/39\">",
"     39",
"    </a>",
"    ]. The rate of prescribing benzodiazepines had declined over that time, while antidepressant prescriptions had increased. For many anxious patients, a combination of antidepressant and benzodiazepine medications may be the most effective treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"sedative-hypnotics\" refers to a heterogeneous class of drugs that include benzodiazepines, barbiturates, and various hypnotics. Barbiturates are now largely limited to induction of anesthesia, while benzodiazepines are widely used for purposes other than sedation, including the treatment of anxiety, insomnia, and epilepsy (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Barbiturates reversibly suppress the activity of the central nervous system (CNS) along a dose-dependent continuum. The therapeutic index for the sedative effects of the barbiturates is low, with general CNS depression linked to the desired therapeutic effects (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Barbiturates'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Older sedative hypnotics, including chloral hydrate (Noctec), ethchlorvynol (Placidyl), ethinamate (Valmid), glutethimide (Doriden), meprobamate (Miltown, Equanil), methyprylon (Noludar), and paraldehyde (Paral), have no place in contemporary medical practice due to their low therapeutic index and high abuse potential (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Other sedatives and hypnotics'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Benzodiazepines work primarily through their effects on GABA receptors. Pharmacologic differences in distribution, elimination, metabolic breakdown pathways and molecular structure account for differences in clinical effects (",
"      <a class=\"graphic graphic_table graphicRef65653 \" href=\"UTD.htm?39/16/40205\">",
"       table 1",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H6\">",
"       'Benzodiazepines'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Drugs with more rapid speed of onset, due to rapid absorption",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      penetration of the blood-brain barrier, are more likely to be abused.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       Diazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      have relatively rapid onset of action and can produce euphoria whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=see_link\">",
"       clorazepate",
"      </a>",
"      and prazepam have inactive parent compounds and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"       oxazepam",
"      </a>",
"      also has a slower onset of activity (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Speed of onset'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      and various benzodiazepines (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"       triazolam",
"      </a>",
"      ) are substrates of the 3A4 enzyme. Simultaneous use of a benzodiazepine that competes with methadone for oxidative pathways in the liver produces higher peak levels of methadone in the blood and brain, referred to as a \"boosting\" effect.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"       oxazepam",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"       temazepam",
"      </a>",
"      are cleared largely by the kidneys, have fewer P450 interactions and are better choices for patients with hepatic impairment or taking multiple medications (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"       \"Pharmacotherapy for generalized anxiety disorder\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Benzodiazepines with shorter elimination half-lives are more likely to produce acute withdrawal on abrupt cessation after prolonged use.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       Alprazolam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"       oxazepam",
"      </a>",
"      are more rapidly eliminated than are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14023?source=see_link\">",
"       clorazepate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/3/27703?source=see_link\">",
"       flurazepam",
"      </a>",
"      , prazepam, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      . Abrupt discontinuation is not appropriate for benzodiazepine discontinuation after prolonged daily use (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"       \"Pharmacotherapy for generalized anxiety disorder\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tolerance to the sedative and euphoric effects of the benzodiazepines develops rapidly; tolerance does not develop to the antianxiety and antipanic effects. Non-addicted medical patients who use a benzodiazepine to treat chronic anxiety obtain beneficial effects at constant, standard, low doses.",
"     </li>",
"     <li>",
"      Zolpidem, zaleplon, and eszopiclone are rapid-onset, short duration of action drugs that act on the benzodiazepine receptors of the GABA system and have largely replaced the benzodiazepines as hypnotic medicines. Eszopiclone has a half-life of five hours, appears to have relatively low abuse potential, and is approved for long-term use (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Benzodiazepine-related hypnotics'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Anxiety disorders are the most prevalent class of mental disorders in the United States. Prescription rates for benzodiazepines peaked in the mid 1970s. Three-fourths of those with anxiety disorder in one community study were receiving no treatment at all. Attitudes against use of benzodiazepines may be depriving many anxious patients of appropriate treatment (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Pharmacoepidemiology'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Baldessarini, RJ. Depression and anxiety disorders. In: Hardman, JG, Limbird, LE (Eds), Goodman and Gilman's: The pharmacological basis of therapeutics, 10th ed, McGraw-Hill, New York 2001. p.447.",
"    </li>",
"    <li>",
"     Charney, DS, Minic, SJ, Harris, RA. Hypnotics and sedatives. In: Hardman, JG, Limbird, LE (Eds), Goodman and Gilman's: The pharmacological basis of therapeutics, 10th ed, McGraw-Hill, New York 2001. p.399.",
"    </li>",
"    <li>",
"     World Health Organization. The use of essential drugs: Third report of the World Health Organization expert committee (WHO Technical Report Series No. 770), Geneva 1988.",
"    </li>",
"    <li>",
"     www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=520 (Accesssed July 30, 2007).",
"    </li>",
"    <li>",
"     Side effects of sleep drugs. Available at www.fda.gov/consumer/features/sleepdrugs073107.html (Accessed August 29, 2007).",
"    </li>",
"    <li>",
"     Handelsman, L. Anxiety in the context of substance abuse. In: Stein, DJ, Hollander, E (Eds), Textbook of anxiety disorders, American Psychiatric Press, Washington, DC 2002. p.441.",
"    </li>",
"    <li>",
"     DuPont, RL. Benzodiazepines: The social issues, Institute for Behavior and Health, Rockville, MD 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/8\">",
"      Abuse of benzodiazepines: The problems and the solutions. A report of a Committee of the Institute for Behavior and Health, Inc. Am J Drug Alcohol Abuse 1988; 14 (Suppl 1):1.",
"     </a>",
"    </li>",
"    <li>",
"     Juergens, SM, Cowley, DS. The pharmacology of benzodiazepines and other sedative-hypnotics. In: Graham, AW, Schultz, TK, Mayo Smith, MF, Ries, RK (Eds), Principles of addiction medicine, 3rd ed, American Society of Addiction Medicine, Chevy Chase, MD 2003. p.119.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/10\">",
"      Weintraub M, Singh S, Byrne L, et al. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991; 266:2392.",
"     </a>",
"    </li>",
"    <li>",
"     Sussman, N, Stein, DJ. Pharmacotherapy for generalized anxiety disorder. In: Stein, DJ, Hollander, E (Eds), Textbook of anxiety disorders, American Psychiatric Press, Washington, DC 2002. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/12\">",
"      Sibille E, Pavlides C, Benke D, Toth M. Genetic inactivation of the Serotonin(1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety. J Neurosci 2000; 20:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/13\">",
"      Weiss M, Tikhonov D, Buldakova S. Effect of flumazenil on GABAA receptors in isolated rat hippocampal neurons. Neurochem Res 2002; 27:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/14\">",
"      Burt DR, Kamatchi GL. GABAA receptor subtypes: from pharmacology to molecular biology. FASEB J 1991; 5:2916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/15\">",
"      Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 1999; 19:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/16\">",
"      Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse. Psychopharmacology (Berl) 1997; 134:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/17\">",
"      Woods JH, Katz JL, Winger G. Use and abuse of benzodiazepines. Issues relevant to prescribing. JAMA 1988; 260:3476.",
"     </a>",
"    </li>",
"    <li>",
"     Griffiths, RR, Sannerud, CA. Abuse of and dependence on benzodiazepines and other anxiolytic/sedative drugs. In: Meltzer, H, Bunney, BS, Coyle, JT (Eds), Psychopharmacology: The third generation of progress, Raven Press, New York 1987. p.1535.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/19\">",
"      Stahl SM. At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. J Clin Psychiatry 2003; 64:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/20\">",
"      Sellers EM, Ciraulo DA, DuPont RL, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatry 1993; 54 Suppl:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/21\">",
"      Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/22\">",
"      Wang PS, Bohn RL, Glynn RJ, et al. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001; 158:892.",
"     </a>",
"    </li>",
"    <li>",
"     DuPont, RL. Getting tough on gateway drugs: A guide for the family, American Psychiatric Press, Washington, DC 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/24\">",
"      Nagy LM, Krystal JH, Charney DS, et al. Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. J Clin Psychopharmacol 1993; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/25\">",
"      Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004; 18 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/26\">",
"      Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991; 52:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/27\">",
"      Svitek J, Heberlein A, Bleich S, et al. Extensive craving in high dose zolpidem dependency. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/28\">",
"      Paparrigopoulos T, Tzavellas E, Karaiskos D, Liappas I. Intranasal zaleplon abuse. Am J Psychiatry 2008; 165:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/29\">",
"      Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/30\">",
"      DuPont RL. Anxiety and addiction: a clinical perspective on comorbidity. Bull Menninger Clin 1995; 59:A53.",
"     </a>",
"    </li>",
"    <li>",
"     DuPont, RL, DuPont, CM, Rice, DP. Economic costs of anxiety disorders. In: Stein, DJ, &amp; Hollander, E (Eds), Textbook of anxiety disorders, American Psychiatric Press, Washington, DC 2002. p.365.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/32\">",
"      Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/33\">",
"      Harman JS, Rollman BL, Hanusa BH, et al. Physician office visits of adults for anxiety disorders in the United States, 1985-1998. J Gen Intern Med 2002; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/34\">",
"      Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2005; 35:1747.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Results from the 2001 National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD 2002.",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Monitoring the Future overview of key findings, National Institutes of Health, National Institute on Drug Abuse, Rockville, MD 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/37\">",
"      Stowell KR, Chang CC, Bilt J, et al. Sustained benzodiazepine use in a community sample of older adults. J Am Geriatr Soc 2008; 56:2285.",
"     </a>",
"    </li>",
"    <li>",
"     Mellinger, GD, Balter, MB. Prevalence and patterns of use of psychotherapeutic drugs: Results from a 1979 national survey of American adults. In: Tognoni, G, Bellantuono, C, Lader, M (Eds), Epidemiological impact of psycho-tropic drugs, Elsevier, Amsterdam 1981. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/42/24232/abstract/39\">",
"      Olfson M, Marcus SC, Wan GJ, Geissler EC. National trends in the outpatient treatment of anxiety disorders. J Clin Psychiatry 2004; 65:1166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7813 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24232=[""].join("\n");
var outline_f23_42_24232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL CONTEXT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other sedatives and hypnotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Speed of onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Persistence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Reinforcement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Benzodiazepine-related hypnotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHARMACOEPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonmedical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Medical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7813\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7813|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/16/40205\" title=\"table 1\">",
"      Pharmacology benzodiazepines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_42_24233="Histology lung 1A answer";
var content_f23_42_24233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54745%7EID%2F69585%7EID%2F81839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54745%7EID%2F69585%7EID%2F81839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of an hematoxylin and eosin-stained section of lung (low power) from a patient with histoplasmosis. Note the granuloma and inflammation in the surrounding lung tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Silver-stained section of same lung tissue (x1000) shows the blackish staining yeast forms of Histoplasma capsulatum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histoplasmosis in the spleen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin-stained section of splenic tissue (x1000) obtained from a patient with overwhelming histoplasmosis, who presented with pneumonia. A macrophage in the center of the slide contains many yeast forms of Histoplasma capsulatum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24233=[""].join("\n");
var outline_f23_42_24233=null;
var title_f23_42_24234="Intertriginous erythrasma";
var content_f23_42_24234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51713%7EDERM%2F80242%7EDERM%2F59529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51713%7EDERM%2F80242%7EDERM%2F59529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical image of red-brown plaques of erythrasma in the groin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. John L. Aeling.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 24-year-old male presented with erythematous plaques in the axillae. A Wood's lamp examination was positive for coral red fluorescence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Kosman Sadek Zikry, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 40-year-old diabetic male presented with red-brown patches in the axillae that resolved with erythromycin therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Jayakar Thomas, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24234=[""].join("\n");
var outline_f23_42_24234=null;
var title_f23_42_24235="Predictors of disorders";
var content_f23_42_24235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictors of anxiety or depressive disorders in patients with physical symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Multiple physical symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Three or more unexplained symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Pain symptoms in two or more regions of the body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Multiple functional somatic syndromes (eg, irritable bowel syndrome or fibromyalgia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic or recurrent physical symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent use of health care (ie, clinic or emergency department visits, hospitalizations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Medication history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Polypharmacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Failure to respond to multiple medication trials for the same symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Intolerance of multiple medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-rated health is fair to poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severity of physical symptom is high (6 or more on a 10-point scale with 0 as none and 10 as unbearable)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physician views clinical encounter as difficult",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24235=[""].join("\n");
var outline_f23_42_24235=null;
var title_f23_42_24236="Comparison of reconstructive materials";
var content_f23_42_24236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of reconstructive materials",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Graft type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Synthetic",
"       </td>",
"       <td>",
"        <p>",
"         Accessible: easy to manufacture and obtain",
"        </p>",
"        <p>",
"         Consistent: materials are reproducible",
"        </p>",
"        <p>",
"         Durable",
"        </p>",
"        <p>",
"         Cost-effective: less expensive to produce than allo- and xenografts",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Infection: microporous and multifilament grafts in particular",
"        </p>",
"        <p>",
"         Erosion: may erode into vagina or viscus",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Autograft",
"       </td>",
"       <td>",
"        <p>",
"         Host response: no risk of rejection",
"        </p>",
"        <p>",
"         No erosion risk: although permanent sutures used to secure may erode",
"        </p>",
"        <p>",
"         Cost-effective",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Limited tissue quantity and quality possible",
"        </p>",
"        <p>",
"         Morbidity: tissue harvest required",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Allograft",
"       </td>",
"       <td>",
"        <p>",
"         Accessible: larger quantities available than autografts, but depends on donor supply",
"        </p>",
"        <p>",
"         No harvest morbidity",
"        </p>",
"        <p>",
"         Low erosion risk",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Infection: theoretical risk of transmission of host pathogens",
"        </p>",
"        <p>",
"         Host response: potential for rejection",
"        </p>",
"        <p>",
"         Inconsistent graft strength",
"        </p>",
"        <p>",
"         Limited durability: processing may weaken material",
"        </p>",
"        <p>",
"         Limited ability to compare among materials",
"        </p>",
"        <p>",
"         Expensive",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Xenograft",
"       </td>",
"       <td>",
"        <p>",
"         Accessible: larger quantities available than autografts",
"        </p>",
"        <p>",
"         No harvest morbidity",
"        </p>",
"        <p>",
"         Low erosion risk",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Infection: theoretical risk of transmission of host pathogens",
"        </p>",
"        <p>",
"         Host response: potential for rejection given nonhuman source",
"        </p>",
"        <p>",
"         Inconsistent graft strength",
"        </p>",
"        <p>",
"         Limited durability: processing may weaken material",
"        </p>",
"        <p>",
"         Cultural issues with porcine or bovine products",
"        </p>",
"        <p>",
"         Expensive",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24236=[""].join("\n");
var outline_f23_42_24236=null;
var title_f23_42_24237="DKA rapid overview";
var content_f23_42_24237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Emergent DKA management in adults: rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Clinical features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DKA usually evolves rapidly over a 24-hour period.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Common, early signs of ketoacidosis include nausea, vomiting, abdominal pain, and hyperventilation. The earliest symptoms of marked hyperglycemia are polyuria, polydipsia, and weight loss.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       As hyperglycemia worsens, neurologic symptoms appear, and may progress to include lethargy, focal deficits, obtundation, seizure, and coma.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Common causes of DKA include: infection; noncompliance, inappropriate adjustment, or cessation of insulin; new onset diabetes mellitus; and myocardial ischemia.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Evaluation and laboratory findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Assess vital signs, cardiorespiratory status, and mental status.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Assess volume status: vital signs, skin turgor, mucosa, urine output.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obtain the following studies: serum glucose, urinalysis and urine ketones, serum electrolytes, BUN and creatinine, plasma osmolality, mixed venous blood gas, electrocardiogram; add serum ketones if urine ketones present.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetic ketoacidosis (DKA) is characterized by hyperglycemia, an elevated anion gap metabolic acidosis, and ketonemia. Dehydration and potassium deficits are often severe.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum glucose is usually greater than 250 mg/dL (13.9 mmol/L) and less than 800 mg/dL (44.4 mmol/L). In certain instances (eg, insulin given prior to ED arrival), the glucose may be only mildly elevated.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Additional testing is obtained based on clinical circumstances and may include: blood or urine cultures, lipase, chest x-ray.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Management",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stabilize the patient's airway, breathing, and circulation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obtain large bore IV (&ge;16 gauge) access; monitor using a cardiac monitor, capnography, and pulse oximetry.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Monitor serum glucose hourly, and basic electrolytes, plasma osmolality, and venous pH every two to four hours until the patient is stable.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Determine and treat any underlying cause of DKA (eg, pneumonia or urinary infection, myocardial ischemia).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Replete fluid deficits:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Give several liters of isotonic (0.9 percent) saline as rapidly as possible to patients with signs of shock.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Give isotonic saline at 15 to 20 mL/kg per hour, in the absence of cardiac compromise, for the first few hours to hypovolemic patients without shock.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; After intravascular volume is restored, give one-half isotonic (0.45 percent) saline at 4 to 14 mL/kg per hour if the corrected serum sodium is normal or elevated; isotonic saline is continued if the corrected serum sodium is reduced.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Add dextrose to the saline solution when the serum glucose reaches 200 mg/dL (11.1 mmol/L).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Replete potassium (K+) deficits:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Regardless of the initial measured serum potassium, patients with DKA have a large total body potassium deficit.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; If initial serum K+ is below 3.3 mEq/L, hold insulin and give K+ 20 to 30 mEq/hour IV until K+ concentration is above 3.3 mEq/L.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; If initial serum K+ is between 3.3 and 5.3 mEq/L, give K+ 20 to 30 mEq per liter IV fluid; maintain K+ between 4 to 5 mEq/L.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; If initial serum K+ is above 5.3 mEq/L do not give K+; check K+ every 2 hours.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Give insulin:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Do not give insulin if initial serum K+ is below 3.3 mEq/L; replete K+ first.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Give all patients without a serum K+ below 3.3 mEq/L regular insulin. Either of two regimens can be used: 0.1 units/kg IV bolus, then start a continuous IV infusion 0.1 units/kg per hour; OR do not give bolus and start a continuous IV infusion at a rate of 0.14 units/kg per hour.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Continue insulin infusion until ketoacidosis is resolved, serum glucose is below 200 mg/dL (11.1 mmol/L), and subcutaneous insulin is begun.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Give sodium bicarbonate to patients with pH below 7.00:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; If the arterial pH is between 6.90 and 7.00, give 50 meq of sodium bicarbonate plus 10 meq of potassium chloride in 200 mL of sterile water over two hours.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; If the arterial pH is below 6.90, give 100 meq of sodium bicarbonate plus 20 meq of potassium chloride in 400 mL sterile water over two hours.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24237=[""].join("\n");
var outline_f23_42_24237=null;
var title_f23_42_24238="Prevalence of gynecomastia";
var content_f23_42_24238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bimodal prevalence of gynecomastia after infancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 270px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prevalence of gynecomastia at various chronologic ages showing peaks at puberty and in older men. The data are derived from multiple population studies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Braunstein, GD, Gynecomastia. In: Diseases of the Breast. Harris, JR, Lippman, ME, Morrow, M, Hellman, S (Eds), Lippincott-Raven, Philadelphia 1996. p. 54.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24238=[""].join("\n");
var outline_f23_42_24238=null;
var title_f23_42_24239="Onset menopausal transition";
var content_f23_42_24239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Onset of the menopausal transition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 351px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Concentrations of FSH, LH, E2, and INH in a volunteer studied at the onset of menopausal transition. The vertical dotted lines represent the times of menses. The horizontal shaded bar represents the young-normal range for FSH. Note the marked fluctuations in hormone levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hee J, MacNaughton J, Bangah M, Burder HG. Perimenopausal patterns of gonadotropins, immunoreactive inhibin, estradiol and progesterone, Maturitas 1993; 18:9. Copyright &copy; 1993 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_42_24239=[""].join("\n");
var outline_f23_42_24239=null;
      